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ABSTRACT 
The delivery of poorly water-soluble bioactives, including active pharmaceutical ingredients (API) and nutraceutical 
components is of great interest for existing drugs and new drug developments, cosmetic formulations, functional foods 
and nutraceuticals. This article presents a novel patented technology called PGX Technology, which utilizes pressurized 
gas expanded (PGX) liquids to dry, micronize, purify and functionalize water-soluble polymers. PGX Technology can 
generate open-porous nanostructured polymer carriers composed of one or several water-soluble polymers forming 
powders, granules, nano-fibrils, aerogels and exfoliated nano-composites with specific surface areas (SSA) ranging from 
tens to several hundred m2/g. Such mesoporous water-soluble carrier systems can be impregnated with a bioactive by 
means of adsorptive precipitation, utilizing supercritical carbon dioxide, leading to the uniform deposition of nano-scale 
particles (<120 nm) throughout the porous matrix, forming a bioactive-polymer complex, for example coenzyme Q10 on 
β-glucan (CoQ10-iBG). A nano-dispersion of CoQ10 is formed when such CoQ10-iBG complex is dissolved in water, 
which is stable over 6 months at room temperature. The bioavailability of the CoQ10-iBG complex tested in rats compared 
favorably with a positive control (CoQ10 in triolein) and a commercial CoQ10-cyclodextrin complex. 
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INTRODUCTION 
Novel strategies for the formulation and processing of 
poorly water-soluble bioactives and drugs range from 
lipid-based colloidal drug delivery systems (DDS) to 
drug nanosuspensions and innovative solid dosage 
forms such as orodispersible films (ODFs) or 
electrospun fiber mats as drug carriers [Göke, 2018]. 
The generation of drug nanosuspensions can be 
achieved by either bottom-up or top-down methods. 
Top-down methods usually start from larger drug 
particles, which are then reduced in size by applying 
mechanical shear, force or cavitation treatment. Top-
down methods employ milling techniques, such as wet 
milling, colloid milling, jet milling or high-pressure 
homogenization methods, such as micro-fluidization or 
a piston gap technique [Chin, 2014; Wais, 2016]. In a 
bottom-up method the drug is typically dissolved first in 
a suitable solvent and then precipitated by changing 
solubility, which can be achieved in several ways, such 
as the addition of an antisolvent. In such antisolvent 
precipitation processes the method of addition and 
mixing of the antisolvent to the solution becomes critical 
and can be achieved by means of rapid mixing devices, 
ranging from simple stirrers to rotating fixed beds, multi 
inlet vortex mixers and confined liquid impinging jets to 
reach highly turbulent and fast mixing thereby 
controlling supersaturation and nucleation [Chan, 2011]. 
Processing techniques using supercritical fluids (SCF) 
to produce drug nanoparticles/nanocrystals have also 
been developed, which take advantage of the highly 
tunable solvent properties of SCFs [Padrela, 2018]. The 
SCF in such process can be utilized as an antisolvent to 
cause precipitation out of a solution, a solvent for the 
solute or as an additive to facilitate atomization and 
drying [Padrela, 2018; Tabernero, 2012]. Moreover, 
SCF processes were developed for particle formation of 
polymers to be used as carrier delivery systems [Yeo, 
2005]. For polymer processing, the SCF can be 
dissolved in a polymer melt and aid in melting point 
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reduction and atomization, such as in the “Particle 
formation from gas-saturated solution” (PGSS) process, 
leading to highly porous polymer particles and 
agglomerates [Yeo, 2005].  
Pressurized Gas eXpanded (PGX) liquid Technology 
has been developed at the University of Alberta 
[Seifried, 2010], is patented in the US, Europe and 
Canada [Temelli & Seifried, 2016 and 2018] and has 
been scaled-up to demo-scale at Ceapro Inc. [Seifried, 
2019]. This platform technology can purify and dry 
aqueous solutions or slurries of polymers into open-
porous nano-structured particles and fibrils utilizing a 
PGX fluid composed of supercritical carbon dioxide 
(SCCO2) and anhydrous ethanol at mild operating 
conditions of 40°C and 100 bar as drying fluid. With the 
PGX Technology, single and multiple polymers can be 
processed by simply blending polymer solutions or 
suspensions to generate exfoliated nano-composites. As 
well, the water-soluble polymers can be further 
modified by cross-linking during the PGX process, 
allowing generation of tailor-made and tunable delivery 
systems. 
The first objective of this work is to present various 
polymers processed by PGX Technology into open-
porous particles, fibrils and nano-composites with large 
specific surface area (SSA). The next objective is to 
demonstrate that such open-porous PGX biopolymer 
carriers can be loaded with a bioactive forming novel 
bioactive impregnated polymer complexes termed 
“impregnated Polymer compleX” (iPX) by means of 
adsorptive precipitation utilizing SCCO2 [Gurikov, 
2018]. Specifically, PGX processed oat β-glucan was 
loaded with the bioactive Coenzyme Q10 (CoQ10), a 
poorly bioavailable lipophilic substance with 
antioxidant activity. The new complex termed CoQ10-
iBG is compared to a commercial CoQ10-cyclodextrin 
complex in terms of water dispersibility and physical 
nanosuspension stability. Finally, a pilot study 
demonstrating the intestinal bioavailability of CoQ10 
was performed to determine the direct in-vivo intestinal 
bioavailability of CoQ10 from the CoQ10-iBG complex 
compared to a standard food grade and commercial 
crystalline CoQ10 formulations using an intestinal-
lymph cannulated rodent model. 
RESEARCH CONCEPT 
Generation of polymer carrier: PGX Technology 
involves the spraying of an aqueous solution or slurry of 
polymer into a pre-pressurized collection chamber, 
together with a PGX fluid, composed of SCCO2 and a 
water-soluble co-solvent/antisolvent (i.e. ethanol, 
acetone or isopropanol) by means of a coaxial nozzle. At 
the processing conditions, the PGX fluid and aqueous 
phase become completely miscible thereby eliminating 
interfacial tension and capillary forces leading to rapid 
precipitation of the polymer and quick removal of the 
water. Thus, open-porous and unique nanoscale  
morphologies can be generated.  
Loading of bioactive onto polymer carrier: The 
porous polymer carrier generated by PGX is then 
subjected to an adsorptive precipitation process utilizing 
SCCO2 to load a bioactive or drug onto the matrix 
[Gurikov, 2018]. In this process, the bioactive is 
essentially solubilized at elevated pressure and suitable 
temperature in SCCO2 and passed through a bed of 
porous polymer carrier previously prepared using the 
PGX Technology. During this step, the SCCO2 with the 
dissolved bioactive or drug can penetrate the entire 
carrier matrix deep into the porous structure, where it 
can interact with the polymer matrix, leading to 
adsorption of the drug on the polymer. Furthermore, by 
modulating the pressure during the adsorptive 
precipitation process a sudden change of solute 
solubility in the SCCO2 solution can be rapidly induced, 
leading to precipitation of nano-scale deposits of the 
bioactive throughout the matrix [Gurikov, 2018]. For 
this study, an open-porous polymer carrier was 
generated by PGX Technology from oat β-glucan (BG) 
and then loaded with CoQ10 by means of adsorptive 
precipitation as described and characterized elsewhere 
[Liu, 2018; Couto, 2018]. 
Helium Ion Microscopy: For imaging the nanoscale 
features of the various PGX-processed polymers and 
impregnated CoQ10-iBG complex a Helium ion 
microscopy (HiM) analysis was performed on a Zeiss 
Orion NanoFab Helium Ion Microscope (Ostalbkreis, 
BW, Germany). Secondary Electron (SE) images were 
collected at 30 kV accelerating voltage and 1.5 pA beam 
current. An electron flood gun was utilized to neutralize 
positive charges accumulated on the sample surfaces, 
which enables direct imaging of insulating materials. 
Stability of aqueous CoQ10 dispersions: Aqueous 
dispersions of the hydrophobic bioactive CoQ10 were 
prepared by dissolving either a commercial CoQ10-γ-
cyclodextrin (CoQ10-CD) complex (CAVAMAX®, 
containing 20% w/w of CoQ10) or the CoQ10-iBG 
complex loaded with 8% w/w of CoQ10 in about 250mL 
of reverse osmosis (RO) water aiming at a CoQ10 
concentration of 0.4 mg/mL by slowly dispersing the 
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powder into pre-heated RO water at 40°C in beakers and 
mixing with a magnetic stirrer. The beakers were then 
covered with parafilm and left to cool to room 
temperature on the lab bench. The dispersions were left 
at room temperature under a dark box to prevent light 
exposure and observed up to 6 months.   
Bioavailability Study: The study design and 
experimental protocol for the intestinal bioavailability 
of CoQ10 from different formulations is shown in 
Figure 1.  
CoQ10 formulations: The bioavailability of CoQ10 
was tested using four formulations: i) 3% w/w CoQ10-
iBG (n=3) pilot test, ii) 8% w/w CoQ10-iBG (n=9), iii) 
20% w/w CoQ10-CD product (n=6) and iv) Food grade 
CoQ10 in triolein (n=6). Each formulation (i-iii) was 
prepared by dispersing the sample in deionized distilled 
water heating and mixing in a water bath at 45°C for 35 
min and cooling to room temperature (~23°C). Since the 
food grade crystalline CoQ10 is insoluble in water, it 
was prepared in triolein (1mL), which represents a 
positive control for absorption of this lipophilic nutrient. 
Each formulation of CoQ10 was administered intra-
gastrically at a dose of ≈10 mg/kg body weight based on 
CoQ10 bioavailability studies in animal and rodent 
models [Hatanaka, 2008; Barakat, 2013]. 
Intestinal bioavailability: The intestinal bioavailability 
of CoQ10 from the CoQ10-iBG complex and standard 
formulations was evaluated using surgical cannulation 
of the stomach and intestinal mesenteric lymphatic 
vessel in a rodent model, which is a direct measure of 
the absorption of lipophilic nutrients and compounds, as 
previously described [Wang, 2012]. Intestinal lymph 
was collected into tubes containing EDTA and stored at 
-80°C for HPLC analyses.
HPLC Analysis of Ubiquinones: HPLC methods were 
established by modifying previously described methods 
for CoQ9 and CoQ10 [Schulz, 2006; Tarry-Adkins, 
2016; Boitier, 1998; Mosca, 2002]. The phylloquinone 
Vitamin K was used as an internal standard and the 
quantitation of CoQ9 and CoQ10 was performed using 
commercial standards to identify and detect these 
ubiquinones in intestinal lymph samples. In brief, total 
lymph ubiquinone (CoQ9 and CoQ10) was oxidized 
with 1,4-benzoquinone, and extracted with 1-propanol 
and then analyzed by reverse-phase HPLC (Agilent 
Poroshell 120, 4.6x100 mm) with UV detection at 275 
nm. Peak areas were analyzed, and CoQ9 and CoQ10 
were quantified using vitamin K as an internal standard 
(1mg/200 mL sample). Validation of the HPLC protocol 
was based on linear calibration curves of each standard 
and 99-100% recovery of the standards; vitamin K, 
CoQ9 and CoQ10 (Thermo Fisher Scientific, DC 
chemicals, Sigma-Aldrich). 
Figure 1: Study design and experimental protocol for 
determining the bioavailability of CoQ10 formulations. 
Bioavailability and Pharmacokinetics: % Total 
absorption of CoQ10, CoQ10 area under the curve 
(CoQ10-AUC), maximum concentration (cMax) were 
determined as previously described [Barakat, 2013; 
Wang, 2012]. % Absorption was adjusted per volume of 
lymph and per hour of collection to reflect 
pharmacokinetics of lymph absorption-bioavailability 
[Wang, 2012; Barakat, 2013]. 
RESULTS 
To demonstrate the capabilities of PGX Technology, 
several biopolymers were processed into open-porous 
structures, which can be impregnated with drugs or 
bioactives and utilized as bioactive delivery systems. 
Some examples are illustrated in Figure 2, showing PGX 
processed corn starch, pectin, sodium alginate, and an 
alginate-pectin exfoliated composite.  
The PGX processed oat β-glucan is displayed in Figure 
3(A) illustrating the open-porous structure. The BG 
carrier was impregnated to generate the CoQ10-iBG 
complex with spherical nanocrystals of CoQ10 with an 
average size of about 92 nm (Figure 3(B)).  
The stability of CoQ10 dispersions in water at room 
temperature is illustrated in Figure 4 after about 18 hours 
(left image) and after 6 months (right image). The 
CoQ10-iBG complex dispersion remained stable for 
more than 6 months at room temperature. 
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Figure 2: HiM images of (A) PGX processed corn 
starch, (B) pectin, (C) sodium alginate, and (D) alginate-
pectin nano-composite. Scale bar length: 200 nm. 
Figure 3: HiM images of (A) open-porous polymer 
carrier generated by PGX Technology from oat β-
glucan, and (B) CoQ10-iBG complex with nanocrystals 
of CoQ10 inside red circle (source: [Liu 2018]). Scale 
bar length: 500 nm. 
Figure 4: Stability of CoQ10 dispersions in water, 
majority of commercial CoQ10-CD (left beaker) 
precipitated in 18.35 hrs (left image), whereas the 
CoQ10-iBG complex (right beaker) was stable for more 
than 6 months (right image). 
Bioavailability of CoQ10 formulations: The results of 
the bioavailability study are shown in Table 1.  
Table 1: CoQ10 bioavailability results for the different 









% Total Abs. 2.43 ±1.01 1.71 ±0.93 4.06 ±2.12 3.27 ±2.06 
cMax (mg/ml) 53.10 ±6.23 27.54 ±7.21 63.82 ±31.04 56.97 ±24.38 
CoQ10-AUC  
(mg/ml) 
67.23 ±35.42 55.63 ±33.53  136.90 ±73.32 133.3 ±65.82 
Figure 5: Absorption kinetics of CoQ10 formulations. 
DISCUSSION 
The CoQ10 area under curve (CoQ10-AUC) was >50% 
higher for both the 8% CoQ10-iBG and 20% CoQ10-
CD formulations compared to the 3% CoQ10-iBG and 
Food CoQ10 in triolein formulations (Table 1).  The data 
show that both BG and cyclodextrin formulations 
increase the absorption of the lipophilic nutrient CoQ10; 
however, the kinetic profile was different with the 8% 
CoQ10-iBG formulation having a delayed maximal 
absorption compared to the 20% CoQ10-CD (Figure 5). 
This may reflect overall faster digestion, including 
gastric emptying of the 20% CoQ10-CD compared to 
the 8% CoQ10-iBG formulation most likely due to the 
higher viscosity of the β-glucan. Due to the fine particles 
of CoQ10 deposited on the BG carrier the bioavailability 
could be enhanced as well, which would agree with a 
previous study where CoQ10 nanocrystals with 80 nm 
diameter had a 7.3-fold increased bioavailability 
compared to a coarse suspension of the bulk drug [Sun, 
2012]. 
CONCLUSIONS 
This work demonstrates the capabilities of PGX 
Technology to generate tailor-made and tunable 
bioactive carrier/delivery systems from water-soluble 
biopolymers. Such biopolymers can be impregnated 
with lipophilic bioactives utilizing SCCO2 assisted 
adsorptive precipitation forming novel iPX 
formulations. Resulting iPX are water dispersible and 
form stable nanodispersions, which, in the case of 
CoQ10, were shown to be more bioavailable. Use of 
other polymers, polymer combinations, and cross-linked 
polymers can lead to improved delivery and release 
profiles of drugs/bioactives, which is our ongoing 
investigation. 
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